Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneTina Green, Michael Møller, Ken H. Young et al.|Journal of Clinical Oncology|2012Cited by 682
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Jooryung Huh et al.|Blood|2013Cited by 677
PD-1 expression and clinical PD-1 blockade in B-cell lymphomasZijun Y. Xu‐Monette, Ken H. Young|Blood|2017Cited by 429
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell LymphomaMark W. Clemens, Roberto N. Miranda, L. Jeffrey Medeiros et al.|Journal of Clinical Oncology|2015Cited by 418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Lin Wu et al.|Blood|2012Cited by 390